Your browser doesn't support javascript.
loading
Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in Males.
Martini, Alberto; Falagario, Ugo Giovanni; Russo, Antonio; Mertens, Laura S; Di Gianfrancesco, Luca; Bravi, Carlo Andrea; Vollemaere, Jonathan; Abdeen, Muhammad; Mendrek, Mikolaj; Kjøbli, Eirik; Buse, Stephan; Wijburg, Carl; Touzani, Alae; Ploussard, Guillaume; Antonelli, Alessandro; Schwenk, Laura; Ebbing, Jan; Vasdev, Nikhil; Froelicher, Gabriel; John, Hubert; Canda, Abdullah Erdem; Balbay, Mevlana Derya; Stoll, Marcel; Edeling, Sebastian; Witt, Jorn H; Leyh-Bannurah, Sami-Ramzi; Siemer, Stefan; Stoeckle, Michael; Mottrie, Alexander; D'Hondt, Frederiek; Crestani, Alessandro; Porreca, Angelo; van der Poel, Hendrik; Decaestecker, Karel; Gaston, Richard; Peter Wiklund, N; Hosseini, Abolfazl.
Afiliação
  • Martini A; Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
  • Falagario UG; Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy; Department of Urology, Karolinska University Hospital, Solna, Sweden.
  • Russo A; Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy; Department of Urology, Clinique Saint Augustin, Bordeaux, France.
  • Mertens LS; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Di Gianfrancesco L; Oncological Urology, IRCCS Veneto Institute of Oncology, Padua, Italy.
  • Bravi CA; Department of Urology, OLV Hospital, Aalst, Belgium; Orsi Academy, Ghent, Belgium.
  • Vollemaere J; Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.
  • Abdeen M; Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.
  • Mendrek M; Department of Urology, Pediatric Urology and Urologic Oncology, St. Antonius Hospital Gronau, Gronau, Germany.
  • Kjøbli E; Department of Urology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Buse S; Department of Urology, Alfried Krupp Krankenhaus, Essen, Germany.
  • Wijburg C; Department of Urology Rijnstate Hospital, Arnhem, The Netherlands.
  • Touzani A; Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France; Department of Urology, International Center of Oncology, Casablanca, Morocco.
  • Ploussard G; Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
  • Antonelli A; Department of Urology, University of Verona, Verona, Italy.
  • Schwenk L; Department of Urology, University Hospital Basel, Basel, Switzerland.
  • Ebbing J; Department of Urology, University Hospital Basel, Basel, Switzerland.
  • Vasdev N; Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK.
  • Froelicher G; Department of Urology, Cantonal Hospital Winterthur, Winterthur, Switzerland.
  • John H; Department of Urology, Cantonal Hospital Winterthur, Winterthur, Switzerland.
  • Canda AE; Department of Urology, Koç University School of Medicine, Istanbul, Turkey.
  • Balbay MD; Department of Urology, Koç University School of Medicine, Istanbul, Turkey.
  • Stoll M; Department of Urology, Vinzenz Hospital, Hannover, Germany.
  • Edeling S; Department of Urology, Vinzenz Hospital, Hannover, Germany.
  • Witt JH; Department of Urology, Pediatric Urology and Urologic Oncology, St. Antonius Hospital Gronau, Gronau, Germany.
  • Leyh-Bannurah SR; Department of Urology, Pediatric Urology and Urologic Oncology, St. Antonius Hospital Gronau, Gronau, Germany.
  • Siemer S; Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.
  • Stoeckle M; Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.
  • Mottrie A; Department of Urology, OLV Hospital, Aalst, Belgium; Orsi Academy, Ghent, Belgium.
  • D'Hondt F; Department of Urology, OLV Hospital, Aalst, Belgium; Orsi Academy, Ghent, Belgium.
  • Crestani A; Oncological Urology, IRCCS Veneto Institute of Oncology, Padua, Italy.
  • Porreca A; Oncological Urology, IRCCS Veneto Institute of Oncology, Padua, Italy.
  • van der Poel H; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Decaestecker K; Department of Urology, AZ Maria Middelares Hospital, Ghent, Belgium; Department of Urology, Ghent University Hospital, Ghent, Belgium.
  • Gaston R; Department of Urology, Clinique Saint Augustin, Bordeaux, France.
  • Peter Wiklund N; Department of Urology, Karolinska University Hospital, Solna, Sweden.
  • Hosseini A; Department of Urology, Karolinska University Hospital, Solna, Sweden. Electronic address: abolfazl.hosseini@ki.se.
Eur Urol ; 84(5): 484-490, 2023 11.
Article em En | MEDLINE | ID: mdl-37117109
ABSTRACT

BACKGROUND:

Little is known regarding functional outcomes after robot-assisted radical cystectomy (RARC) and intracorporeal neobladder (ICNB) reconstruction.

OBJECTIVE:

To report on urinary continence (UC) and erectile function (EF) at 12 mo after RARC and ICNB reconstruction and investigate predictors of these outcomes. DESIGN, SETTING, AND

PARTICIPANTS:

We used data from a multi-institutional database of patients who underwent RARC and ICNB reconstruction for bladder cancer. SURGICAL PROCEDURE The cystoprostatectomy sensu stricto followed the conventional steps. ICNB reconstruction was performed at the physician's discretion according to the Studer/Wiklund, S pouch, Gaston, vescica ileale Padovana, or Hautmann technique. The techniques are detailed in the video accompanying the article. MEASUREMENTS The outcomes measured were UC and EF at 12 mo. RESULTS AND

LIMITATIONS:

A total of 732 male patients were identified with a median age at diagnosis of 64 yr (interquartile range 58-70). The ICNB reconstruction technique was Studer/Wiklund in 74%, S pouch in 1.5%, Gaston in 19%, vescica ileale Padovana in 1.5%, and Hautmann in 4% of cases. The 12-mo UC rate was 86% for daytime and 66% for nighttime continence, including patients who reported the use of a safety pad (20% and 32%, respectively). The 12-mo EF rate was 55%, including men who reported potency with the aid of phosphodiesterase type 5 inhibitors (24%). After adjusting for potential confounders, neobladder type was not associated with UC. Unilateral nerve-sparing (odds ratio [OR] 3.85, 95% confidence interval [CI] 1.88-7.85; p < 0.001) and bilateral nerve-sparing (OR 6.25, 95% CI 3.55-11.0; p < 0.001), were positively associated with EF, whereas age (OR 0.93, 95% CI 0.91-0.95; p < 0.001) and an American Society of Anesthesiologists score of 3 (OR 0.46, 95% CI 0.25-0.89; p < 0.02) were inversely associated with EF.

CONCLUSIONS:

RARC and ICNB reconstruction are generally associated with good functional outcomes in terms of UC. EF is highly affected by the degree of nerve preservation, age, and comorbidities. PATIENT

SUMMARY:

We investigated functional outcomes after robot-assisted removal of the bladder in terms of urinary continence and erectile function. We found that, in general, patients have relatively good functional outcomes at 12 months after surgery.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Derivação Urinária / Neoplasias da Bexiga Urinária / Robótica / Procedimentos Cirúrgicos Robóticos / Disfunção Erétil Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Derivação Urinária / Neoplasias da Bexiga Urinária / Robótica / Procedimentos Cirúrgicos Robóticos / Disfunção Erétil Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article